Women with pathogenic variants (PVs) in cancer-predisposing genes such as BRCA1, BRCA2, PALB2, CHEK2 and ATM, have an increased risk of developing breast cancer (BC), and those with PVs in BRCA1, BRCA2 and PALB2 also have an increased risk of epithelial ovarian cancer (EOC), which is the representative histological type of hereditary ovarian cancer for these genes [1]. The gene discussed is BRCA2; the disease is cancer.